These charts warn that there is something wrong with the American consumer
Consumer discretionary and retail stocks are underperforming at an alarming rate, defying many calls about consumers’ strength
All Posts in "News Team"
Stocks close lower as trade-fight concerns linger, yield-curve inversion deepens
Bond yields slide, and the U.S. Treasury yield curve inverts further
Equities Analysts Issue Forecasts for AptarGroup, Inc.’s Q3 2019 Earnings (NYSE:ATR)
AptarGroup, Inc. (NYSE:ATR) – Research analysts at William Blair cut their Q3 2019 earnings per share (EPS) estimates for shares of AptarGroup in a research report issued on Thursday, August 1st, according to Zacks Investment Research. William Blair analyst J. Andersen now forecasts that the industrial products company will post earnings of $0.94 per share for the quarter, down from their previous forecast of $1.07. William Blair also issued estimates for AptarGroup’s Q4 2019 earnings at $0.99 EPS, FY2019 earnings at $4.15 EPS and FY2020 earnings at $4.55 EPS.
Equities Analysts Offer Predictions for Independence Contract Drilling Inc’s Q2 2019 Earnings (NYSE:ICD)
Independence Contract Drilling Inc (NYSE:ICD) – Research analysts at Capital One Financial issued their Q2 2019 earnings estimates for shares of Independence Contract Drilling in a research note issued to investors on Thursday, August 1st, according to Zacks Investment Research. Capital One Financial analyst L. Lemoine expects that the oil and gas company will post earnings per share of ($0.02) for the quarter. Capital One Financial also issued estimates for Independence Contract Drilling’s Q3 2019 earnings at ($0.02) EPS, Q4 2019 earnings at $0.00 EPS and FY2020 earnings at $0.02 EPS.
Equities Analysts Cut Earnings Estimates for Dunkin Brands Group Inc (NASDAQ:DNKN)
Dunkin Brands Group Inc (NASDAQ:DNKN) – Investment analysts at Piper Jaffray Companies dropped their Q3 2019 earnings estimates for Dunkin Brands Group in a report released on Thursday, August 1st, Zacks Investment Research reports. Piper Jaffray Companies analyst N. Regan now forecasts that the restaurant operator will post earnings of $0.81 per share for the quarter, down from their prior forecast of $0.82. Piper Jaffray Companies also issued estimates for Dunkin Brands Group’s FY2019 earnings at $3.05 EPS, Q2 2020 earnings at $0.92 EPS, Q3 2020 earnings at $0.86 EPS and FY2020 earnings at $3.26 EPS.
Equities Analysts Set Expectations for Occidental Petroleum Co.’s FY2020 Earnings (NYSE:OXY)
Occidental Petroleum Co. (NYSE:OXY) – Investment analysts at Capital One Financial reduced their FY2020 earnings per share estimates for Occidental Petroleum in a report released on Thursday, August 1st, according to Zacks Investment Research. Capital One Financial analyst R. Tullis now anticipates that the oil and gas producer will earn $3.71 per share for the year, down from their prior estimate of $3.74.
Japan’s Move to Lower South Korea Trade Status Takes Effect
Japan’s downgrading of South Korea’s trade status has taken effect, a decision that already set off reaction and hurt bilateral relations.
Volvo’s Polestar Opens China Factory to Export to Europe, US
Volvo’s electric brand Polestar going ahead with plans to export Chinese-made cars to the US despite trade tension.
Malaysia Ex-PM Use ‘Elaborate’ Plan to Loot Fund: Prosecutor
Former Malaysian Prime Minister Najib Razak’s second corruption trial has started, with a prosecutor alleging he pilfered billions of dollars from the 1MDB state investment fund through an “elaborate charade”.
Cyprus Aims for Gas Generated Electricity by Late 2021
An official says Cyprus is aiming to have the infrastructure in place to generate electricity using natural gas by the end of 2021.
Weekly Market Review – May 18, 2024
Gain Therapeutics’ clinical Parkinson’s drug restores motor function in mice
Eli Lilly axes next-generation, resistance-busting RET inhibitor
What’s behind the rise of colorectal cancer in younger adults? Bacteria may have the answer
Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks
Dexcom adds upgraded One+ glucose monitoring system to European slate
Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026
Kyverna raises IPO expectations by $100M, now eyeing almost $300M for latest biotech listing of 2024
After Incyte’s commercial buy, Novartis shells out €2.7B for cancer specialist MorphoSys